Ziliotto Nicole, Lencioni Sara, Cirinciani Martina, Zanardi Alan, Alessio Massimo, Soldà Giulia, Da Pozzo Eleonora, Asselta Rosanna, Caricasole Andrea
Department of Pharmacy, University of Pisa, Via Bonanno 6, Pisa 56126, Italy.
Department of Pharmacy, University of Pisa, Via Bonanno 6, Pisa 56126, Italy; Department of Research & Innovation, Kedrion Biopharma S.p.A, Via di Fondovalle, Loc. Bolognana, Gallicano 55027, Italy.
EBioMedicine. 2025 Mar;113:105625. doi: 10.1016/j.ebiom.2025.105625. Epub 2025 Mar 4.
Aceruloplasminemia (ACP) is a rare recessive disease caused by loss of ceruloplasmin activity due to pathogenic variants in the ceruloplasmin (CP) gene. ACP causes iron accumulation in various organs, leading to neurodegeneration, anaemia, and diabetes. Estimating ACP prevalence is challenging, particularly as missense variants are not readily identified as pathogenic.
Heterozygous missense variants likely to impact function were mapped in gnomAD and representative examples analysed for effects on CP activity. This knowledge was complemented by prediction of destabilizing effects of potentially pathogenic missense variants and integrated with loss-of-function mutations. Global ACP prevalence was predicted and compared with a more traditional method.
Several as yet uncharacterised missense CP variants of pathogenic interest were identified by structure-function in-silico analysis. A representative subset was functionally validated, together with known ACP missense variants. Insights on the relative importance of copper ions coordinating centres in CP and its substrate specificity were discovered. Overall, a destabilizing effect was predicted for 130 missense CP variants. This information, integrated with known ACP missense and loss-of-function CP variants in gnomAD, allowed an estimation of ACP prevalence of 12.6/10. An alternative analysis based on minor allele frequency ≤0.01 resulted in an ACP prevalence as high as 8/10.
These prevalence estimates for ACP are 20-25-fold higher than previously estimated and underscore the applicability of structure-function based analyses of real-world genetic variability to provide an alternative method for representing the frequency of rare disease variants.
REACT-EU PON 2014-2021, Kedrion S.p.A.
无铜蓝蛋白血症(ACP)是一种罕见的隐性疾病,由铜蓝蛋白(CP)基因的致病变异导致铜蓝蛋白活性丧失引起。ACP导致铁在各个器官中蓄积,进而引发神经退行性变、贫血和糖尿病。估计ACP的患病率具有挑战性,尤其是因为错义变异不容易被确定为致病性变异。
在gnomAD中定位可能影响功能的杂合错义变异,并分析代表性实例对CP活性的影响。通过预测潜在致病性错义变异的不稳定效应并与功能丧失突变相结合,补充了这一知识。预测全球ACP患病率,并与一种更传统的方法进行比较。
通过结构-功能计算机模拟分析,鉴定出了几个尚未表征的具有致病意义的错义CP变异。一个代表性子集以及已知的ACP错义变异在功能上得到了验证。发现了关于CP中铜离子配位中心的相对重要性及其底物特异性的见解。总体而言,预测130个错义CP变异具有不稳定效应。这些信息与gnomAD中已知的ACP错义变异和功能丧失的CP变异相结合,得出ACP患病率估计为12.6/10万。基于次要等位基因频率≤0.01的另一种分析得出ACP患病率高达8/10万。
这些ACP患病率估计值比之前估计的高20至25倍,并强调了基于结构-功能分析现实世界遗传变异性以提供一种表示罕见病变异频率的替代方法的适用性。
REACT-EU PON 2014 - 2021,凯德里昂股份公司